Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : Findings from Bristol-Myers Squibb Reveals New Findings on Immunoglobulins (Drug-to-antibody determination for an antibody-drug-conjugate utilizing...

share with twitter share with LinkedIn share with facebook
share via e-mail
02/24/2017 | 06:01pm CET

Findings from Bristol-Myers Squibb Reveals New Findings on Immunoglobulins (Drug-to-antibody determination for an antibody-drug-conjugate utilizing cathepsin B digestion coupled with reversed-phase high-pressure liquid chromatography analysis)

By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Immunology - Immunoglobulins have been presented. According to news originating from Bloomsbury, New Jersey, by NewsRx correspondents, research stated, "Antibody drug conjugates or ADCs are currently being evaluated for their effectiveness as targeted chemotherapeutic agents across the pharmaceutical industry. Due to the complexity arising from the choice of antibody, drug and linker; analytical methods for release and stability testing are required to provide a detailed understanding of both the antibody and the drug during manufacturing and storage."

Our news journalists obtained a quote from the research from Bristol-Myers Squibb, "The ADC analyzed in this work consists of a tubulysin drug analogue that is randomly conjugated to lysine residues in a human IgG1 antibody. The drug is attached to the lysine residue through a peptidic, hydrolytically stable, cathepsin B cleavable linker. The random lysine conjugation produces a heterogeneous mixture of conjugated species with a variable drug-to-antibody ratio (DAR), therefore, the average amount of drug attached to the antibody is a critical parameter that needs to be monitored. In this work we have developed a universal method for determining DAR in ADCs that employ a cathepsin B cleavable linker. The ADC is first cleaved at the hinge region and then mildly reduced prior to treatment with the cathepsin B enzyme to release the drug from the antibody fragments, This pre-treatment allows the cathepsin B enzyme unrestricted access to the cleavage sites and ensures optimal conditions for the cathepsin B to cleave all the drug from the ADC molecule. The cleaved drug is then separated from the protein components by reversed phase high performance liquid chromatography (RP-HPLC) and quantitated using UV absorbance. This method affords superior cleavage efficiency to other methods that only employ a cathepsin digestion step as confirmed by mass spectrometry analysis."

According to the news editors, the research concluded: "This method was shown to be accurate and precise for the quantitation of the DAR for two different random lysine conjugated ADC molecules."

For more information on this research see: Drug-to-antibody determination for an antibody-drug-conjugate utilizing cathepsin B digestion coupled with reversed-phase high-pressure liquid chromatography analysis. Journal of Chromatography A, 2017;1481():44-52. Journal of Chromatography A can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Chromatography A - www.journals.elsevier.com/journal-of-chromatography-a/)

The news correspondents report that additional information may be obtained from M. Adamo, Bristol Myers Squibb, Bloomsbury, NJ 08551, United States. Additional authors for this research include G.Y. Sun, D.F. Qiu, J. Valente, W.K. Lan, H.T. Song, M. Bolgar, A. Katiyar and G. Krishnamurthy (see also Immunology - Immunoglobulins).

Keywords for this news article include: Bloomsbury, New Jersey, United States, North and Central America, Cysteine Endopeptidases, Essential Amino Acids, Enzymes and Coenzymes, Drugs and Therapies, Diamino Amino Acids, Peptide Hydrolases, Basic Amino Acids, Drug Development, Immunoglobulins, Blood Proteins, Cathepsin B, Cathepsins, Immunology, Antibodies, Lysine, Bristol-Myers Squibb.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
02/24 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Reveals New Findings o..
02/24 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Report Recent Findi..
02/24 BRISTOL MYERS SQUIBB : Trademark Application for "APOTHECON" Filed by Bristol-My..
02/24 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Update Understanding o..
02/23 BRISTOL MYERS SQUIBB : Prices $1.5 Billion of Senior Notes
02/22 Newmont and Papa John's dip; Bristol-Myers and Garmin rise
02/22DJBRISTOL MYERS SQUIBB : New Pressure on Drug Giant -- WSJ
02/22DJWHAT'S NEWS : Business & Finance -- WSJ
02/22 BRISTOL MYERS SQUIBB : Icahn Takes Stake In Bristol-Myers
02/22DJBRISTOL MYERS SQUIBB : Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Upd..
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/24 BIOTECH FORUM DAILY DIGEST : Trevena Oversold? Bristol-Myers Squibb On The Block..
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/24 FDA OKs Intellipharmaceutics' generic metformin; shares ahead 40% premarket
02/23 Is Pfizer's Research Pipeline Truly Undervalued?
02/22 ALLERGAN'S SAUNDERS : No interest in Valeant
Financials ($)
Sales 2017 19 720 M
EBIT 2017 5 198 M
Net income 2017 4 660 M
Finance 2017 422 M
Yield 2017 2,88%
P/E ratio 2017 20,41
P/E ratio 2018 18,73
EV / Sales 2017 4,77x
EV / Sales 2018 4,55x
Capitalization 94 408 M
More Financials
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,4 $
Spread / Average Target -1,9%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.11.86%182 412
More Results